Mandate

Vinge has advised XVIVO in conjunction with its directed share issue of SEK 440 million.

September 14, 2023 M&A

Vinge has advised XVIVO Perfusion AB in connection with its directed share issue at a subscription price of SEK 275 per share which corresponded to the closing price of XVIVO’s shares on Nasdaq Stockholm on the day of the issue.

XVIVO received SEK 440 million before issue costs. The subscription price was determined through an accelerated bookbuilding procedure arranged by Carnegie and DNB Markets. Investors in the directed share issue were both existing and new shareholders such as Bure Equity AB, the Fourth Swedish National Pension Fund, Swedbank Robur Fonder, Eccenovo, Handelsbanken Fonder, Tredje AP-fonden and a Tier-1 global international investor.

Vinge's team primarily consisted of Anders Strid and project manager Edin Agic.

 

Related

Vinge advises Fortinova Fastigheter AB (publ) on its first SEK 200 million green bond issue

Vinge has advised Fortinova Fastigheter AB (publ) (“Fortinova”) on the company’s first issue of senior unsecured green bonds in an aggregate principal amount of SEK 200 million, under a framework of up to SEK 600 million. Nordea, acted as sole bookrunner in connection with the bond issue.
September 18, 2026

Vinge advises Morrow Bank AB (publ) in connection with the bank’s sale of parts of MedMera Bank and the sale of NPL portfolios

Vinge has advised Morrow Bank AB (publ) in connection with the divestment of parts of MedMera Bank’s operations to a leading global credit investment firm. The divestment is structured as a sale of shares and priced at a premium of approximately SEK 90 million above equity value as per the completion date. The transaction includes parts of MedMera’s banking operations such as IT infrastructure, organisation and management, whilst Morrow Bank retains MedMera’s performing loans, deposits, customers, the MedMera brand, the Coop partnership agreement as well as key personnel.
September 15, 2026

Vinge advises HealthCap in conjunction with its investment in AMRA Medical

HealthCap is investing in AMRA Medical AB, a company that analyses whole-body MRI images to classify and quantify an individual’s muscle and fat tissue throughout the body and places this in relation to human health and disease.
September 15, 2026